Trials / Conditions / Relapsed Diffuse Large B-Cell Lymphoma

Relapsed Diffuse Large B-Cell Lymphoma

18 registered clinical trials studyying Relapsed Diffuse Large B-Cell Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Epcoritamab-CAR T Cells for Large B-cell Lymphomas NCT06458439	Abramson Cancer Center at Penn Medicine	Phase 2
Completed	Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination NCT05267054	BeiGene	Phase 1 / Phase 2
Withdrawn	Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant NCT05222438	Barbara Ann Karmanos Cancer Institute	Phase 2
Active Not Recruiting	Copanlisib Plus Venetoclax in R/R DLBCL NCT04572763	Dana-Farber Cancer Institute	Phase 1 / Phase 2
Completed	Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibi NCT05068440	BeiGene	Phase 2
Recruiting	DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relap NCT04920617	ImmunoVaccine Technologies, Inc. (IMV Inc.)	Phase 2
Recruiting	DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489	Miltenyi Biomedicine GmbH	Phase 2
Active Not Recruiting	Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in S NCT04833114	GWT-TUD GmbH	Phase 3
Unknown	Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL NCT04659434	Qian Wenbin	Phase 2
Active Not Recruiting	Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapse NCT04384484	ADC Therapeutics S.A.	Phase 3
Completed	A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma NCT03688152	Incyte Corporation	Phase 1
Terminated	PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Tr NCT03488251	Molecular Templates, Inc.	Phase 2
Completed	Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL NCT03305445	Icahn School of Medicine at Mount Sinai	Phase 1
Terminated	Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitabl NCT03422523	University Hospital Southampton NHS Foundation Trust	Phase 2
Terminated	A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymp NCT03136497	Hackensack Meridian Health	Phase 1
Completed	Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) NCT02658968	Nordic Nanovector	Phase 1
Completed	Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgk NCT02348216	Kite, A Gilead Company	Phase 1 / Phase 2
Completed	Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse L NCT02077166	Pharmacyclics LLC.	Phase 1 / Phase 2